Alumis Inc. (ALMS) is a prominent player in the aluminum sector, specializing in the development and commercialization of high-performance aluminum solutions for automotive, aerospace, and construction industries. By harnessing proprietary technologies and a commitment to sustainability, Alumis not only drives innovation in materials science but also prioritizes environmental responsibility. The company's strong focus on research and development enables it to adapt to emerging market trends, resulting in a diverse product portfolio designed to meet the dynamic needs of its clients. With a commitment to operational excellence, Alumis is well-positioned to achieve sustained growth and deliver long-term value for investors.
| Revenue (TTM) | $7.40M |
| Gross Profit (TTM) | $7.40M |
| EBITDA | $-421.45M |
| Operating Margin | -6440.00% |
| Return on Equity | -93.60% |
| Return on Assets | -45.30% |
| Revenue/Share (TTM) | $0.06 |
| Book Value | $3.52 |
| Price-to-Book | 7.25 |
| Price-to-Sales (TTM) | 446.15 |
| EV/Revenue | 393.92 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -37.70% |
| Shares Outstanding | $129.44M |
| Float | $98.56M |
| % Insiders | 0.52% |
| % Institutions | 94.37% |
Volatility is currently contracting
– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO –
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms –
Alumis Inc. is upgraded to Buy, reversing a prior Sell, based on strong Phase 3 envudeucitinib psoriasis data and pipeline potential. Envudeucitinib demonstrated efficacy comparable to JNJ's newly approved Icotyde, with 74% PASI 75 and 59% sPGA 0/1 at week 16. ALMS targets NDA submission for envudeucitinib in 2H 2026, with additional data in psoriatic arthritis and SLE expected in 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ALMS and any ticker you trade — then tracks every position and per-strategy win rate.
